Medical Education
February 2013 View as a webpage | Forward to a colleague | Not subscribed? Subscribe here
Advances in Transplantation
Featured Articles

Risk-stratified adoptive cellular therapy after HCT for CLL

This study examined outcomes of 50 consecutive patients with chronic lymphocytic leukemia (CLL) transplanted after reduced-intensity conditioning followed by pre-emptive donor lymphocyte infusions (DLI) with the intention of reducing the risk of GVHD. At a median follow-up of 4.3 years, 4-year overall and progression-free survival was 75% and 65%, respectively. DLI was associated with a 29% cumulative incidence of severe GVHD and mortality of 6.4%.The authors conclude that “directed delivery of allogeneic cellular therapy has the potential to induce durable remissions in high-risk CLL without incurring excessive GVHD.”

Richardson SE, et al. Br J Haematol

HCT for chemorefractory mantle cell lymphoma

This study examined 202 adults with chemotherapy-unresponsive mantle cell lymphoma (MCL) who underwent allogeneic HCT between 1998 and 2010 and whose outcomes were reported to CIBMTR (Center for International Blood and Marrow Transplant Research). Patients received either myeloablative (n=74) or reduced intensity/non-myeloablative conditioning (n=128). Univariate analyses found that intensity of the conditioning regimen had no significant effect on three-year non-relapse mortality, relapse/progression, progression-free survival, and overall survival. Three-year overall survival using myeloablative and reduced intensity/non-myeloablative conditioning was 25% and 30%, respectively (p=0.45). The authors conclude that “despite a refractory disease state, approximately a fourth of MCL patients can attain durable remissions after allo-HCT.”

Hamadani M, et al. Biol Blood Marrow Transplant

AZA and DLI for relapsed AML/MDS after HCT

A first salvage therapy combining azacitidine (AZA) with donor lymphocyte infusions (DLI) in relapsed transplant recipients has a 30% response rate, according to results of a recent study. This multicenter study of patients with acute myeloid leukemia (AML; n=28) and myelodysplastic syndromes (MDS; n=2) had a treatment schedule of up to eight cycles of AZA followed by DLI after every second AZA cycle. A median of three AZA courses were administered, and 22 patients (73%) received DLI. Overall response rate was 30%: seven complete remissions (23%) and two partial remissions (7%). The authors conclude that AZA and DLI can induce long-term remissions and can be a suitable salvage therapy for patients with AML or MDS relapsing after allogeneic HCT.

Schroeder T, et al. Leukemia

“How I assess comorbidities prior to HCT”

Previous studies have shown the prognostic value of the hematopoietic cell transplantation-comorbidity index (HCT-CI), which measures the prevalence and severity of organ impairments in patients considering HCT. To ensure consistent HCT-CI scores among different evaluators, a web-based training program has been developed that utilizes consistent guidelines and systematic scoring methods. In a test of the training program, 88 randomly selected HCT recipient records at a single institution were confidentially re-scored by evaluators using the web-based program. The inter-evaluator agreement on HCT-CI scores was high, with weighted kappa values of 0.89-0.97.

Sorror ML. Blood


One million transplants worldwide

On January 30, the Worldwide Network for Blood and Marrow Transplantation (WBMT) announced the landmark achievement of the 1 millionth blood stem cell transplant worldwide. The total includes all peripheral blood, marrow, and cord blood transplants, both autologous and allogeneic, performed worldwide since 1957.

“One million transplants is a milestone that may surprise many people, because blood stem cell transplants were viewed as a rare procedure until the last decade or so,” said Dietger Niederwieser, M.D., president of the WBMT and professor of medicine at the University Hospital of Leipzig, Germany.

Learn more about this landmark achievement


New research at ASH shows comparable survival in unrelated and related donor HCT

Read a special edition of Advances in Transplantation summarizing the latest research in hematopoietic cell transplantation presented at the American Society of Hematology (ASH) Annual Meeting.

Research highlights include:

  • Comparable survival in unrelated, related donor HCT
  • Post-HCT azacitidine can lower chronic GVHD
  • Improvement in survival after unrelated donor HCT
  • Read about these topics and more: ASH Annual Meeting highlights (PDF).
    Test Your Knowledge

    How many transplants are performed worldwide each year?

    Answer Now
    Other Noteworthy Articles
    Auto- and allo-HCT for Burkitt lymphoma

    Access abstract

    Race and ethnicity in decisions about unrelated stem cell donation

    Access abstract

    NIH chronic GVHD scoring system

    Access abstract

    Cost of allogeneic and autologous HCT in the U.S.

    Access abstract

    Review: Validation of GVHD biomarkers

    Access abstract

    Resources For You
    CME: Post-transplant care
    MDS FS

    Earn 0.75 CME credits through an online activity on post-transplant care jointly sponsored by Medscape Education Oncology and the National Marrow Donor Program (NMDP). Review risk factors associated with exposures and late effects, guidelines for head-to-toe assessment, and screening and vaccination schedules. Take CME

    Resources For Your Patients
    Online patient community
    Patients Connect image

    Are you looking for ways to help your patients connect with others like them? Invite them to visit the Be The Match Patients Connect Facebook Page to connect with a community of more than 2,000 transplant patients, caregivers, and families. Visit now

    Visit Us Online

    Access outcomes data slides, CME, clinical references, patient education and more.

    Contact Us | Privacy Policy | Terms of Use | Unsubscribe | Vol. 13, No. 2

    Advances in Transplantation is an electronic newsletter published monthly by the National Marrow Donor Program (NMDP). This newsletter is sent only to those individuals who have requested to receive clinical education updates from NMDP.

    If this e-mail message was forwarded to you and you'd like Advances in Transplantation delivered directly to you, please subscribe.

    If you are a member of the NMDP Be The Match Registry, unsubscribing to the Advances in Transplantation e-newsletter does not change your status on the registry. The NMDP may still contact you by e-mail, postal mail or telephone if a patient needs you or to request that you update your address.

    National Marrow Donor Program, 3001 Broadway St. N.E., Minneapolis, MN 55413 | 1 (612) 627-5800 | Copyright 2013

    Copyright © 1996-2018 National Marrow Donor Program. All Rights Reserved.